Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice.
Sharma AX, Quittner-Strom EB, Lee Y, Johnson JA, Martin SA, Yu X, Li J, Lu J, Cai Z, Chen S, Wang MY, Zhang Y, Pearson MJ, Dorn AC, McDonald JG, Gordillo R, Yan H, Thai D, Wang ZV, Unger RH, Holland WL. Sharma AX, et al. Among authors: thai d. Cell Rep. 2018 Feb 13;22(7):1760-1773. doi: 10.1016/j.celrep.2018.01.065. Cell Rep. 2018. PMID: 29444429 Free PMC article.
Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure.
Gao C, Ren SV, Yu J, Baal U, Thai D, Lu J, Zeng C, Yan H, Wang Y. Gao C, et al. Among authors: thai d. JACC Basic Transl Sci. 2019 Mar 13;4(2):161-172. doi: 10.1016/j.jacbts.2018.11.001. eCollection 2019 Apr. JACC Basic Transl Sci. 2019. PMID: 31061918 Free PMC article.
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Pettus J, et al. Among authors: thai d. Nat Med. 2022 Oct;28(10):2092-2099. doi: 10.1038/s41591-022-02011-x. Epub 2022 Oct 3. Nat Med. 2022. PMID: 36192552 Free PMC article. Clinical Trial.
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Pettus J, et al. Among authors: thai d. Nat Med. 2023 Nov;29(11):2959. doi: 10.1038/s41591-023-02301-y. Nat Med. 2023. PMID: 36932248 No abstract available.
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, Garcia CA, Velayo AC, Jorgensen B, Biermann D, Tsai D, Green J, Zaffryar-Eilot S, Holzer A, Ogg S, Thai D, Neufeld G, Van Vlasselaer P, Smith V. Barry-Hamilton V, et al. Among authors: thai d. Nat Med. 2010 Sep;16(9):1009-17. doi: 10.1038/nm.2208. Epub 2010 Sep 5. Nat Med. 2010. PMID: 20818376
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Shah MA, et al. Among authors: thai d. J Clin Oncol. 2021 Mar 20;39(9):990-1000. doi: 10.1200/JCO.20.02755. Epub 2021 Feb 12. J Clin Oncol. 2021. PMID: 33577358 Free PMC article. Clinical Trial.
110 results